Request Demo
Last update 05 Nov 2026
Molgramostim biosimilar(Xiamen Amoytop Biotech Co. Ltd.)
Last update 05 Nov 2026
Overview
Basic Info
Drug Type Biosimilar, Colony-stimulating factors |
Synonyms Molgramostim biosimilar, molgramostim follow-on biologic, Recombinant Human Granulocyte/Macrophage Colony-stimulating Factor + [7] |
Target |
Action stimulants |
Mechanism CSF-2R stimulants(Granulocyte-macrophage colony-stimulating factor receptor stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (31 Dec 1997), |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 1191632844
The sequence is quoted from: *****
Related
1
Clinical Trials associated with Molgramostim biosimilar(Xiamen Amoytop Biotech Co. Ltd.)NCT01232504
Effect of Granulocyte-macrophage Stimulating Factor on Prevention and Treatment of Invasive Fungal Diseases in the Recipients of Allogeneic Stem Cell Transplantation: A Prospective Multicenter Randomized Phase 4 Trial
100 Clinical Results associated with Molgramostim biosimilar(Xiamen Amoytop Biotech Co. Ltd.)
Login to view more data
100 Translational Medicine associated with Molgramostim biosimilar(Xiamen Amoytop Biotech Co. Ltd.)
Login to view more data
100 Patents (Medical) associated with Molgramostim biosimilar(Xiamen Amoytop Biotech Co. Ltd.)
Login to view more data
100 Deals associated with Molgramostim biosimilar(Xiamen Amoytop Biotech Co. Ltd.)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D05066 | Molgramostim biosimilar(Xiamen Amoytop Biotech Co. Ltd.) |
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Leukopenia | China | 31 Dec 1997 | |
| Myelodysplastic Syndromes | China | 31 Dec 1997 | |
| Neutropenia | China | 31 Dec 1997 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 4 | 206 | (rhGM-CSF Group) | exmhsnmqtc = dsvigrybkr cwzvoirkgq (nwqtoniaxl, elncgsnoqe - yisftjwtpv) View more | - | 27 Oct 2014 | ||
rhG-CSF (rhG-CSF Group) | exmhsnmqtc = idnnsoupbq cwzvoirkgq (nwqtoniaxl, jucxnwtatg - oxtniroygf) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free